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ABSTRACT 
 
Background: During the past several decades, there has been a steady increase in the frequency of isolation of 
Candida spp. from blood stream infections from NICU worldwide. Furthermore, monitoring programs have detected 
an increase in the prevalence of infections caused by non albicans Candida (NAC). NAC are reported to be 
intrinsically resistant and less susceptible to empirically used azoles like Fluconazole. Thus speciation and 
antifungal susceptibility testing become imperative for these isolates. Objective: To study the trend in species 
distribution and antifungal susceptibility pattern among blood stream Candida strains isolated from neonatal 
intensive care patients was the aim of the study. Method: Susceptibility testing of clinically significant Candida 
isolates to various antifungal was performed by E-test in accordance with manufacturer instructions. The results 
obtained were analyzed and compared. Results: The most frequently isolated species was Candida tropicalis 
(52.83%) followed by Candida parapsilosis (16.98%), Candida albicans (9.4%), Candida glabrata (9.4%), 
Candida krusei (7.5%) and Candida guilliermondii (3.77%). Overall sensitivity of 85%, 81%, 26%, and 98% 
respectively to Amphotericin B, Fluconazole, Itraconazole and Voriconazole was found. Conclusion: The study 
shows the clinical significance and mycological shift of Candida species in blood culture of the neonatal population 
with a predominance of NAC species. Voriconazole showed an excellent activity and can be used in empirical 
treatment for candidemia rather than Fluconazole.  
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Introduction  
 
Over the past few decades, there has been a significant 
increase in blood stream Candida isolates particularly 
in patients admitted to ICU [1,2].It is the third most 
common cause of late-onset sepsis in NICU patients 
and accounts for 9-13% of blood stream infections 
(BSI) in neonates[3]. The reported mortality rates for 
infants with neonatal candidiasis lies between 25 and 
50% compared to an overall mortality of 4.7% for all 
NICU admissions [4]. Infants in NICU are at risk of 
candidemia and development of various other new 
infections. 
_______________________________ 
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The risk factors for candidemia are low gestational age, 
low APGAR scores, gestational diabetes, human 
immunodeficiency virus infection/acquired immune 
deficiency syndrome (HIV/AIDS) and congenital 
malformations [4,5]. 
Further, the association of colonization with Candida 
due to intravenous or urinary catheterization in this 
vulnerable group has been identified as an important 
risk factor with high predictive value for the 
development of invasive disease. Until recently, C. 
albicans was by far the predominant species in most 
countries, causing up to two thirds of all cases of 
invasive candidiasis. Furthermore, monitoring 
programs have detected an increase in the prevalence 
of infections caused by NAC (especially C. 
parapsilosis, C.  glabrata, and C.  krusei) and other 
yeast genera [1].This shift is relevant because some of 
these species have reduced susceptibility or intrinsic 
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resistance to fluconazole, as is the case  for C. glabrata 
and C. krusei, respectively. A worrisome finding is the 
increasing incidence of cross-resistance to newer 
triazoles among fluconazole resistance species [6]. 
Thus speciation and antifungal susceptibility (AFS) 
testing become imperative for these isolates. 
Unfortunately, data about prevalence or antifungal 
susceptibility patterns in NICU patients with 
candidaemia are scarce, and empirical treatment in 
neonates with suspicion of Candida infection 
frequently has to be instituted by extrapolating 
information from the adult. The aim of this study was 
to study the species distribution and antifungal 
susceptibility pattern among blood stream Candida 
strains isolated from infants from neonatal intensive 
care unit at a tertiary care centre in Eastern Uttar 
Pradesh.  
 
Material and methods 
The proposed study is a cross-sectional study was 
carried out in the Department of Microbiology and 
Paediatrics of S. S. Hospital BHU Varanasi from June 
2013 to June 2014. The study population consisted of 
499 neonates admitted to the paediatrics department 
with complaints of fever, low birth weight, and 
prematurity. Prior consent was taken from every baby’s 
guardian before sample collection and the study was 
approved by the ethical committee. 
Inclusion &exclusion criteria: Eligible for 
participation in the study were neonates who had been 
hospitalized for >48 h and had developed candidemia 
during their ICU stay. Neonates receiving or who had 
received prior antifungal therapy the last month before 
the ICU admission and patients with a confirmed 
systemic fungal infection prior to the diagnosis of 
candidemia also were excluded from the study. 
 Candidaemia definition: Candidaemia or invasive 
candidiasis was defined by a positive culture for yeast 
obtained from blood drawn from peripheral vein and 
presence of relevant clinical signs and symptoms. 
Blood samples (n=499) were obtained aseptically in 
BHI broth. It was incubated at 370 C. After 48 hours 
incubation subculture was done on two Sabouraud’s 
Dextrose Agar slope containing chloramphenicol and 
incubated at 250 C and at 370 C for 7days. The culture 
tubes were examined daily for 1 week. Similarly, the 
second subculture was done after 7-day incubation of 
BHI broth and final subculture (for those samples 
which showed no growth after 7 days) on 28 days 
incubation. Colonies suggestive of Candida in SDA 
tube were further identified and speculated by 
morphological and biochemical tests like germ-tube 
test, chlamydospores formation, sugar fermentation 
test, and sugar assimilation test. [7]Anti-fungal 
susceptibility was done on supplemented Muller 
Hinton agar with 2% glucose and methylene blue 
(0.5μg/ml) by E-test as per manufacturer's instructions 
using gradient strips of Amphotericin B, Fluconazole, 
Itraconazole, and Voriconazole obtained from HiMedia 
Mumbai India. The concentration gradient for 
fluconazole ranged from 256 to 0.016 μg/ml while for 
other drugs was 32 to 0.002 μg/ml.   
Analysis of the results 
The MICs of four antifungal agents: Amphotericin B, 
Fluconazole, Voriconazole, and Itraconazole were 
analyzed. Breakpoints chosen for Fluconazole (  <8 
µg/ml, susceptible   S  ; 16–32 µg/ml, susceptible-dose 
dependent   SDD  ;  > 64 µg/ml, resistant   R  ), 
Voriconazole ( <1 µg/ml, S; 2 µg/ml, SDD;  > 4 µg/ml, 
R)were as per the Clinical and Laboratory Standards 
Institute (CLSI M27 S3) [8] . Since no breakpoints 
have been published for Amphotericin B and 
Itraconazole, breakpoints chosen were Amphotericin B 
( < 1 µg/ml, S; 2 µg/ml, I;  > 4 µg/ml, R), and 
Itraconazole (< 0.125 µg/ml, S; 0.25-0.5µg/ml, I; > 
1µg/ml, R) as in a study by Nguyen  et al  and Rex et al 
respectively [9,10]        
 
Results  
A total of 53(10.62%) out of 499 samples were culture 
positive for Candida species. Candida tropicalis 
no(52.83%), Candida parapsilosis (16.98%), Candida 
albicans (9.4%), Candida glabrata (9.4%), Candida 
krusei (7.5%) and Candida guilliermondii (3.77%) 
were the  species causing candidemia , in order of 
frequency of isolation shown in figure 1. No mixed 
infection was found. In vitro susceptibility testing 
results of 53 Candida isolates against Amphotericin B, 
Fluconazole, Voriconazole, and Itraconazole by E-test 
method is shown in table 1. Voriconazole showed 
excellent activity against the isolates, with a 
susceptibility of 98% (MIC < 1 µg/ml). The proportion 
of isolates for which Amphotericin B MIC was <1 
µg/ml were 84.9% (45). Eight isolates (15%) had MIC 
> 4µg/ml. For Fluconazole the percentages of isolates 
in each category (S, SDD, and R) were 81%, 0%, 19%. 
Itraconazole exhibited the least activity against 
Candida isolates, showing a resistance of 25%. Seven 
isolates of C. tropicalis, two isolates of each of C. 
krusei and C. parapsilosis one isolate each of C. 
albicans and C. glabrata were found resistant to 
Itraconazole (MIC > 64 µg/ml).  
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Discussion 
Neonatal candidemia has gained significant importance 
and has increased the concern in past two decades. In 
our study, out of 499 clinical samples a total of 
53(10.6%) Candida isolates were obtained. This 
finding was in accordance with an Indian study 
involving 660 neonates admitted to NICU of a teaching 
hospital where the culture positivity for Candida was 
found to be 13.6% [11]. Comparing the results of the 
present study with previous year’s record from our 
center, a shift in terms of increase in the number of 
NAC species from bloodstream was found. This 
finding is consistent with other studies where non-
albicans Candida species predominate in the Indian 
subcontinent, Asia, and Europe [12-14]. Many neonatal 
ICU studies in the past have reported C. parapsilosis as 
the predominant pathogen causing candidemia in 
neonates [15, 16]. Overall, the predominant Candida 
species isolated in this study was C. tropicalis (53%). 
A similar study in India conducted by Narang et al also 
showed that the isolation of C. tropicalis was highest 
(41%) [17].The reasons for this change may be either 
of the two. First, there has been an increase in the 
number of high-risk patients, namely, immune 
suppressed patients due to diverse causes and types of 
medication, and patients requiring invasive devices and 
antibiotics [18]. Second, however, as suggested by a 
majority of studies, the selection of NAC strains in this 
cohort of patients is due to the use of Fluconazole for 
long-term prophylaxis which is common practice in our 
setup. [19, 20].In this study, we have found eight 
Candida isolates less susceptible and probably resistant 
to Amphotericin B (MIC > 4µg/ml). Despite more than 
five decades of use of the polyene antifungals, AMB 
resistance in Candida spp. is rare, but it is slowly 
increasing, probably in correlation with the increased 
consumption of Amphotericin B [21]. Previous Studies 
have shown that C. glabrata, C. guilliermondii, C. 
krusei, and C. lusitaniae have a higher propensity than 
other Candida spp. to possess or develop resistance to 
Amphotericin B.  The findings in our study differ here 
as reduced susceptibility to Amphotericin B was found 
in six C.tropicalis and two C. parapsilosis isolates [22]. 
This is probably because Candida tropicalis and C. 
parapsilosis are among the predominant species of 
Candida isolated from BSI in our study. The activity of 
fluconazole against Candida species remains low 
comment (resistance of 19 %) 81% were sensitive as 
indicated by our study. Resistance to Fluconazole was 
found among four isolates each of C. tropicalis and C. 
krusei, and two C. glabrata. Fluconazole resistance has 
always been a subject of concern in the predominantly 
BSI isolates of Candida like C. glabrata and Candida 
tropicalis [23]. Increase isolation of blood stream C. 
krusei, known to be intrinsically resistant to 
Fluconazole has worsened the situation [24]. Different 
rates of resistance to Fluconazole were detected in 
Candida strains from different parts of the country, but 
the finding of Kumar CP et al was consistent with our 
study [25-27].Cross-resistance between Fluconazole 
and Voriconazole has also been frequently reported in 
many species, nevertheless, Voriconazole exhibited 
excellent in vitro antifungal activity and no resistance 
was found against it in our study [28] Itraconazole 
showed least in vitro antifungal activity, against the 
isolates in this study. The resistant rate of the isolates 
to Itraconazole in this study was 25% which is 
consistent with the findings of Kothari et al [25]. A 
majority of the isolates (74 %) had a MIC of >0.12 
μg/ml. It seems that long-term Fluconazole prophylaxis 
may have a role in partially selecting less-susceptible 
isolates to Itraconazole.  
Conclusion 
The study shows the clinical significance and 
mycological shift of Candida species in blood culture 
of the neonatal population with a predominance of 
NAC species. The high usage of Fluconazole as 
prophylactic agent appeared to have played a role in 
this shift, however, it may be recognized that other 
events like patient specific risk factors might have also 
contributed to the selection of different species. The 
results of the present studies on azole susceptibility 
testing of Candida species have shown that 
Voriconazole should be used in empirical treatment for 
candidemia rather fluconazole. Furthermore, species-
level identification of Candida isolates and continuous 
surveillance of antifungal susceptibility is necessary to 
monitor trends and to choose the correct empiric 
therapy. 
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Fig 1: Distribution of blood stream Candida spp. isolated from Neonatal Intensive Care Unit 
Table 1: Antifungal susceptibility testing results of 53 fungal isolates by E-Test method 
Isolate N
o 
AMB FLC ITR VRC 
S I R S SD
D 
R S I R S SD
D 
R 
C .tropicalis 28 2 0 6 24 0 4 5 16 7 27 1 0 
C. parapsilosis 9 7 0 2 9 0 0 2 5 2 9 0 0 
C. glabrata 5 5 0 0 3 0 2 4 0 1 5 0 0 
C. albicans 5 5 0 0 5 0 0 2 2 1 5 0 0 
C. krusei 4 4 0 0 0 0 4 1 1 2 4 0 0 
C. 
guilliermondii 
2 2 0 0 2 0 0 0 2 0 2 0 0 
Total (%) 53 45(85) 0 8(15
) 
43(81) 0 10(19
) 
14(26
) 
26(49) 13(25
) 
52(98) 1(2) 0 
AMB=Amphotericin B; FLC=Fluconazole; ITR=Itraconazole; VRC=Voriconazole; S=Sensitive; I= Intermediate; 
R=Resistance; SDD; Sensitive dose dependent.  
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